Beyond the Standard: Individualized Approaches to Dual Antiplatelet Therapy Gain Attention
Dirk Sibbing, Professor, Cardiologist and Angiologist at Privatklinik Lauterbacher Mühle and LMU Munich, shared an insightful post on LinkedIn:
”When it comes to dual antiplatelet treatment we are still using a non-individualized approach in our everyday clinical practice for patients after PCI.
However, evidence is accumulating that sex, age, BMI and many more variables may constitute relevant treatment effect modifiers for drugs like clopidogrel, prasugrel or ticagrelor.
See the latest data on DAPT and sex in the European Heart Journal and my Editorial that puts the findings into perspective.”
Read the full article here.
Article: Dual antiplatelet therapy modulation strategies beyond standard of care: a promising path towards individualized antiplatelet treatment
Author: Dirk Sibbing
Stay updated on all science in the field of hematology with Hemostasis Today.
-
May 23, 2026, 14:48Sam Zeraatain Nejad Davani: Off-Pump Surgery for COVID-19 Right Atrial Thrombosis
-
May 23, 2026, 14:42How Should Evidence Be Interpreted in Modern Hemophilia Care? – GARDEN
-
May 23, 2026, 12:52Fernanda Orsi: Honor to Be Speaking on ITP Diiferential Diagnosis at the 2026 Highlights of ASH
-
May 23, 2026, 12:46Jayagowri Karthikeyan: Grateful to Receive NBEMS President’s Gold Medal for Excellence In Immunohematology and Blood Transfusion
-
May 23, 2026, 12:40Aryabhatta Sadhu: Redefining Transfusion Medicine Across Obstetrics, Gynecology, and Fetal Medicine
-
May 23, 2026, 12:03Kiana Mohammadian: Do Anti-Inflammatory Cytokines Modulate Thrombosis?
-
May 23, 2026, 11:55Zikra Tazeen Mohammad Zakriya: Exploring the Link Between Vitamin D, Stroke, and Thrombosis
-
May 23, 2026, 11:33Alessandra Bosch: Swiss Delphi Consensus Study on Thrombophilia Testing Indications
-
May 23, 2026, 11:21Dip Ghosh: How CPDA-1 Keeps Transfusions Safe and Effective